Technical Articles

PD-L1 targeted antibodies, as the core force of tumor immunotherapy, restore the killing ability of T cells against tumors by blocking the immunosuppressive binding of PD-L1 and PD-1. Currently, it has become the standard treatment for 16 specific cancers and unlimited indications.

Programmed death receptor 1 (PD-1) is a core member of the immune checkpoint family, mainly expressed on the surface of activated immune cells. It transmits immunosuppressive signals by binding to PD-L1/PD-L2, maintaining peripheral immune tolerance. But tumor cells often overexpress PD-L1 and achieve "immune escape" through the PD-1 pathway. Inhibitors targeting PD-1/PD-L1 have become a revolutionary approach in cancer treatment, and in recent years, research has expanded to include factors affecting efficacy, combination therapy, new mechanisms, and other dimensions, providing new directions for precision immunotherapy

As an important member of the TIM family (TIM1/HAVCR1, TIM3/HAVCR2, TIM4/TIMD4), TIM-3 has attracted much attention for its critical role in autoimmune and tumor immune regulation